application of sars-cov-2 ngs · 2020. 5. 8. · b.3 b.4 5.0e-5 • • • • ongoing ......

12
Application of SARS-CoV-2 NGS This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003589.

Upload: others

Post on 24-Jan-2021

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14

Application of SARS-CoV-2 NGS

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003589.

Page 2: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14

Page 3: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14

83 overlappende amplicons 500bp75 bp overlap

Page 4: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14

Page 5: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14
Page 6: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14
Page 7: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14
Page 8: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14
Page 9: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14

Lineage

A

A.2

A.5

B

B.1

B.1.1

B.1.10

B.1.11

B.1.13

B.1.22

B.1.5

B.1.5.2

B.1.7

B.1.8

B.1.9

B.2

B.2.1

B.2.3

B.2.5

B.3

B.45.0E-5

Page 10: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14

Page 11: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14

Ongoing..

• Monitoring of relevant mutations

• Longitudinal monitoring patients

• Househld studies

• Animal studies

Page 12: Application of SARS-CoV-2 NGS · 2020. 5. 8. · B.3 B.4 5.0E-5 • • • • Ongoing ... gadgi-Wuerttgnbgg-1_2020 EPI ISL 412912 2020-02-25 Kanagawa 1_2020 CPI ISL 402126 2020-01-14

Consortium partners